Quest Diagnostics Inc (NYSE:DGX) posted third-quarter adjusted earnings per share of $2.30, beating the consensus of $2.26. Sales increased 8.5% year-over-year to $2.49 billion, beating the consensus of $2.42 billion. Quest Diagnostics saw total revenue growth of 8.5%, including 4.2% organic growth, said Quest Diagnostics CEO Jim Davis. “Our performance was driven by new customer wins and expanded business with physicians and hospitals, as well as recent acquisitions, including LifeLabs,” he added. “We are now on track to complete eight acquisitions by year’s end that meet our criteria for pro…